Final Results

Medcaw Investments PLC

05 March 2026

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN UNION (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

5 March 2026

Medcaw Investments Plc

("Medcaw" or the "Company")

Audited Financial Results for the Year Ended 31 December 2025

Medcaw Investments Plc (LSE: MCI), a company listed on the Main Market of the London Stock Exchange, announces its audited financial results for the year ended 31 December 2025.

The Company's Annual Report and Accounts will be made available on the Company's website at www.medcaw-invest.com.

NOTE: Trading in the Company's shares is temporarily suspended pending publication of the AIM admission document and completion of the proposed Reverse Takeover of the Eagle Lake Gold Project. This announcement is made pursuant to the Company's obligations under the UK Listing Rules.

Key Points

During the Year:

·    Loss before taxation of £144,478 (FY24: £432,360), a reduction of 67%, reflecting the elimination of impairment charges and the waiver of accrued director fees totalling £182,454

·    Basic and diluted loss per share of 0.65p (FY24: 1.95p)

·    Cash and cash equivalents of £320,829 at 31 December 2025 (FY24: £72,286)

·    On 10 September 2025, the Company issued unsecured Convertible Loan Notes ("CLNs") with a total principal value of £550,000 to fund ongoing corporate costs and transaction expenses

·    Board refined investment strategy toward natural resources, focusing on Tier 1 mining jurisdictions

·    On 19 December 2025, the Company entered into binding heads of terms with Ulvestone Ltd for the proposed acquisition of 90% of the Eagle Lake Gold Project, located in Ontario, Canada, by way of Reverse Takeover ("RTO")

Post Year End:

·    Work on the proposed RTO is progressing to plan. Further details of the RTO, including the Notice of General Meeting, will be set out in the Admission Document, which the Company will publish in due course.

Marcus Yeoman, Non-Executive Chairman of Medcaw Investments Plc commented "Following a challenging period, 2025 saw Medcaw take decisive steps to reposition the Company for growth. The Board believes that the proposed acquisition of the Eagle Lake Gold Project in Ontario, if completed, could represent a significant strategic pivot and provide shareholders with exposure to a quality gold asset in a Tier 1 mining jurisdiction. The proposed move to AIM would provide a more suitable platform to deliver long-term value, with access to a broader natural resources investor base. The Board is pleased with the progress being made and looks forward to updating shareholders further in due course."

For further information:

Medcaw Investments plc Charlie Wood (Executive Director)	[phone]
Bowsprit Partners Limited (Broker) Luis Brime John Treacy	[phone]

For more information please visit: www.medcaw-invest.com

About Medcaw Investments Plc

Medcaw Investments Plc (LSE: MCI) is a UK company currently listed on the Main Market of the London Stock Exchange. The Company has agreed, subject to Shareholder approval and Admission, to acquire 90% of Wedgetail Mining Ltd, the holder of the Eagle Lake Gold Project in Ontario, Canada - 95 contiguous mining claims covering approximately 1,986 hectares in the Kenora Mining Division, prospective for orogenic gold mineralisation.

Chairman's Statement

We announced on 2 April 2025 that the Board determined the Company would not proceed with the proposed acquisition of Abyssinian Metals Limited ("AML") as announced on 7 July 2023. The Board reached this conclusion as a result of the ongoing dispute between AML and the Federal Democratic Republic of Ethiopia (including Oromia State), details of which were announced by Medcaw on 8 November 2024.

The Company's shares re-commenced trading on the London Stock Exchange on 2 April 2025.

On 19 December 2025, the Company announced binding heads of terms with Ulvestone Ltd for the proposed acquisition, by way of a Reverse Takeover, of 90% of Wedgetail Mining Ltd ("Wedgetail"), which holds 95 contiguous mining claims comprising the Eagle Lake Gold Project in the Kenora Mining Division, Ontario, Canada, covering approximately 1,986 hectares. The Project is located approximately 27 km west-southwest of Dryden and lies within a historically underexplored greenstone belt that is prospective for orogenic gold mineralisation. The proposed consideration of £4.17 million comprises £170,000 in cash and £4.0 million to be satisfied through the issue of 266,666,667 new ordinary shares at 1.5 pence per share.

The Proposals form part of a wider corporate reorganisation, comprising: (i) cancellation of the Company's listing on the Main Market of the London Stock Exchange; (ii) Admission of the enlarged group to trading on AIM; (iii); and a Placing to fund initial exploration activities and working capital. A Rule 9 Waiver under the City Code on Takeovers and Mergers may be required in connection with the issue of the Consideration Shares.

The proposed acquisition of the Eagle Lake Gold Project represents a significant step forward for Medcaw and signals the start of a more focused growth phase. In an environment of ongoing macro uncertainty, gold continues to demonstrate its defensive qualities, and Ontario offers a stable, mining-friendly jurisdiction with strong infrastructure and regulatory clarity.

The Board believes that combining a high-quality gold asset with a move to AIM will provide the Company with a clearer strategic direction, enhanced market profile and access to a broader natural resources investor base. Subject to completion of the transaction and associated fundraise, the Directors are confident the Company will be appropriately capitalised to advance the Eagle Lake Gold Project and drive the next stage of development.

I would like to thank our shareholders, fellow directors and colleagues for their continued support during this period of significant corporate activity.

Marcus Yeoman

Non-Executive Chairman

4 March 2026

Statement of Comprehensive Income

For the Year Ended 31 December 2025

		Year ended 31 Dec 2025	Year ended 31 Dec 2024
	Note	£	£
Revenue		-	-
Administrative expenses	4	(118,485)	(267,097)
Impairment	11	-	(196,141)
Operating result		(118,485)	(463,238)
Finance income	11/15	(25,993)	30,878
Loss before taxation		(144,478)	(432,360)
Income tax	7	-	-
Loss for the year and total comprehensive loss for the year		(144,478)	(432,360)
Basic and diluted loss per Ordinary Share (pence)	8	(0.65)	(1.95)

The statement has been prepared on the basis that all operations are continuing operations.

Statement of Financial Position

As at 31 December 2025

		As at 31 Dec 2025	As at 31 Dec 2024
	Note	£	£
ASSETS
Current assets
Cash and cash equivalents	9	320,829	72,286
Other current assets	10	44,326	26,191
Total assets		365,155	98,477
Liabilities
Current liabilities
Trade and other payables	12	96,944	261,781
Convertible Loan Notes	15	524,284	-
Total liabilities		621,228	261,781
Net (Liabilities) / Assets		(256,073)	(163,304)
EQUITY AND LIABILITIES
Equity attributable to owners
Ordinary share capital	13	221,320	221,320
Share premium	13	1,005,110	1,005,110
Share based payment reserve	14	14,903	14,903
Convertible Loan Note reserve	15	51,709	-
Accumulated losses		(1,549,115)	(1,404,637)
Total equity and liabilities		(256,073)	(163,304)

Statement of Cash Flows

For the Year Ended 31 December 2025

	Note	Year ended 31 Dec 2025 £	Year ended 31 Dec 2024 £
Cash flows from operating activities
Loss before income tax		(144,478)	(432,360)
Adjustments for:
Impairment	11	-	196,141
Adjustments for changes in working capital:
(Increase)/decrease in trade and other receivables		(18,135)	114,132
Increase/(decrease) in trade and other payables		359,447	19,030
Interest income		-	(30,878)
Net cash from / (used in) operating activities		196,834	(133,935)
Cash flows from financing activities
No financing activities in the year		-	-
Net cash from financing activities		-	-
Cash flows from investing activities
Proceeds from issue of Convertible Loan Notes	15	51,709	-
Loan notes advanced	11	-	(165,263)
Net cash from / (used in) investing activities		51,709	(165,263)
Net increase / (decrease) in cash and cash equivalents		248,543	(299,198)
Cash and cash equivalents at beginning of year		72,286	371,484
Cash and cash equivalents at end of year		320,829	72,286

Important Notice

The financial information set out in this announcement does not constitute statutory accounts within the meaning of Section 434 of the Companies Act 2006. The statutory accounts for the year ended 31 December 2025 were approved by the Board on 4 March 2026 and will be filed with the Registrar of Companies. The auditors' report on those accounts was unqualified, though it contained an emphasis of matter in respect of going concern. The person responsible for arranging the release of this announcement on behalf of the Company is Charles Wood, Executive Director.

Caution regarding forward looking statements

Certain statements in this announcement, are, or may be deemed to be, forward looking statements. Forward looking statements are identified by their use of terms and phrases such as ''believe'', ''could'', "should" ''envisage'', ''estimate'', ''intend'', ''may'', ''plan'', ''potentially'', "expect", ''will'' or the negative of those, variations or comparable expressions, including references to assumptions. These forward-looking statements are not based on historical facts but rather on the Directors' current expectations and assumptions regarding the   Company's future growth, results of operations, performance, future capital and other expenditures (including the amount, nature and sources of funding thereof), competitive advantages, business prospects and opportunities. Such forward-looking statements reflect the Directors' current beliefs and assumptions and are based on information currently available to the Directors.

 

END